Introduction
The rapid development of antibacterial resistance in Streptococcus pneumoniae and Streptococcus pyogenes, particularly over the last decade, is of major clinical concern. Resistance in S. pneumoniae has been reported spanning different classes of antibacterials, principally the penicillins and cephalosporins, and more recently the macrolides. [1] [2] [3] The macrolides have become widely used as initial empirical antibacterial therapy for a variety of community-acquired respiratory tract infections, in response to the rapid evolution of β-lactamresistant S. pneumoniae. 4 Macrolides also provide coverage for the so-called 'atypical' bacterial pathogens Mycoplasma pneumoniae, Chlamydophila (Chlamydia) pneumoniae and Legionella pneumophila, making them particularly well placed for the treatment of community-acquired pneumonia. 4 However, pneumococcal resistance to the macrolides has also evolved rapidly in recent years, and many penicillin-resistant S. pneumoniae now have significantly reduced susceptibility to macrolides. [1] [2] [3] Although penicillin resistance has not been described in S. pyogenes, macrolides are a suitable substitute in acute pharyngitis patients with β-lactam hypersensitivity, or in patients with treatment failure. 5 Macrolide resistance in S. pneumoniae occurs by two mechanisms: target-site modification or efflux of the drug out of the cell. In the most common form of target-site modification, a specific adenine residue on the 23S rRNA (A 2058 -Escherichia coli numbering) is di-methylated by an rRNA methylase. 6 The predominant methylase responsible for macrolide resistance in S. pneumoniae is erm (B) . 7 methylation is thought to lead to a conformational change in the ribosome resulting in decreased binding of all macrolide, lincosamide and streptogramin B antibacterials (the so-called MLS B phenotype). 8,9 erm(A) subclass erm(TR), although common in S. pyogenes, has also recently been reported in S. pneumoniae. 10 Target-site modification may also occur by nucleotide substitutions in the 23S rRNA and in genes that encode the L4 and L22 riboproteins. 11 Mutations at position 2058 or 2059 produce phenotypes that may be identical to those seen with methylases, whilst mutations at other nucleotide positions (such as 2057, 2452 and 2611) have been shown to produce lower-level drug resistance. 11, 12 New phenotypes with mutations at different sites on the 23S rRNA have also been described. For example, a 23S rRNA A2062C mutation in S. pneumoniae that produced resistance to only the 16-membered ring macrolides and streptogramin B has been reported recently. 13 Macrolide efflux is mediated by the product of the mef(A) gene in both S. pneumoniae and S. pyogenes. 9 Isolates with mef(A) usually have macrolide MICs lower than the erm(B) isolates (e.g. erythromycin A MIC of 2-4 mg/L for S. pneumoniae and 1-8 mg/L for S. pyogenes) and retain susceptibility to clindamycin (the so-called M-phenotype). 14 However, erythromycin A MICs of up to 32 mg/L have been reported. 15 The acquisition of both a methylase and an efflux mechanism in the same strain has also been described for both S. pyogenes and S. pneumoniae. 16, 17 Due to overlapping MIC ranges between efflux and target modification mechanisms, extrapolation of genotype from MIC phenotype may not always be reliable, and the detection of dual and/or unknown mechanisms may be masked by a predominant phenotype when MIC testing is used alone.
The aims of this study were to determine the distribution of macrolide resistance mechanisms among recently circulating clinical isolates of S. pneumoniae and S. pyogenes from a global surveillance study (PROTEKT 1999 (PROTEKT -2000 of bacterial respiratory tract pathogens from patients with community-acquired respiratory tract infections. The study also sought to compare the results obtained from PROTEKT with those from previous studies in which macrolide resistance mechanisms were determined genotypically.
Materials and methods

Collecting centres
In the first year of PROTEKT (1999-2000 winter season), the following 69 centres from 25 countries contributed isolates of S. pneumoniae and S. pyogenes: Canada (7), USA (8), Mexico (4), Brazil (7), Argentina (2), Germany (7), the Netherlands (1), Sweden (1), UK (2), Eire (1), Belgium (1), France (4), Portugal (2), Spain (2), Switzerland (2), Italy (2), Austria (1), Turkey (1), Hungary (1), Poland (1), Hong Kong (1), Japan (6), South Korea (2), Australia (2) and Indonesia (1) .
Isolates
Isolates of S. pneumoniae (n = 3362) and S. pyogenes (n = 1485) were collected from patients with community-acquired respiratory tract infections (sinusitis, otitis media, pharyngitis/tonsillitis, pneumonia, acute bacterial exacerbations of chronic bronchitis and acute exacerbation of chronic obstructive airways disease). The following sources were considered acceptable: pus from middle ear fluid, and cultures from blood, sputum, bronchoalveolar lavage, specimens obtained by tympanocentesis, nasopharyngeal swab or aspirate, sinus aspirate and throat swab. The detailed methodology for isolate storage and identification in the PROTEKT study is reported separately. 18 MICs were determined at a central laboratory (GR Micro Ltd, London, UK) for a panel of existing and new antimicrobials, using previously described methods. 18 In brief, we used the NCCLS broth microdilution method with lyophilized microtitre plates (Sensititre; Trek Diagnostics) and an inoculum of 3-7 × 10 4 cfu in 100 µL media. MIC endpoints were read as the lowest concentration of antimicrobial that totally inhibited macroscopically visible growth of the inoculum.
Macrolide resistance mechanism detection
All isolates found to be macrolide resistant (erythromycin A, MIC ≥ 1 mg/L) were tested for the presence of erm(A), erm(A) subclass erm(TR), erm(B), erm(C) and mef(A)
genes using a multiplex rapid cycle polymerase chain reaction (PCR) with microwell-format probe hybridization, as described previously. 19 In addition, three macrolide-susceptible S. pneumoniae and two macrolide-susceptible S. pyogenes were tested from each of the centres involved in the study to investigate the presence of non-expressed macrolide resistance genes.
Results and discussion
In this study, genotypic analysis of macrolide resistance mechanisms in S. pneumoniae and S. pyogenes from a global surveillance study (PROTEKT 1999 (PROTEKT -2000 was undertaken. Although macrolide resistance genotype analysis has been undertaken previously for both S. pneumoniae and S. pyogenes, studies have been limited to either one country or a small number of countries in a defined geographical region. PROTEKT is the first study to produce data on the global distribution of macrolide resistance mechanisms in S. pneumoniae and S. pyogenes.
A total of 1043 macrolide-resistant S. pneumoniae isolates from 25 countries and 143 macrolide-resistant S. pyogenes from 19 countries were tested for the presence of macrolide resistance mechanisms. In addition, a total of 226 isolates of macrolide-susceptible S. pneumoniae and 129 isolates of macrolide-susceptible S. pyogenes were tested to investigate the presence of non-expressed macrolide resistance genes.
S. pneumoniae
In this sub-study of PROTEKT, all the macrolide-susceptible S. pneumoniae isolates tested were negative for the mechanisms under investigation. The distribution of macrolide resistance mechanisms in the 1043 macrolide-resistant S. pneumoniae isolates is shown in Table 1 . A summary of previous studies in which macrolide resistance mechanisms were investigated genotypically is provided in Table 2 . The 1999-2000 data from PROTEKT show that the distribution of macrolide resistance mechanisms varies widely between country and geographical region. The predominant mechanism globally is erm(B) (56.2%) followed by mef(A) (35.3%). In Europe, the predominant mechanism is erm(B), although this varies widely between European countries. France, Belgium and Spain all had >90% erm(B), which is in agreement with previous studies (see Table 2 ). In addition, Turkey, Hungary, Portugal and Poland had similarly high levels of erm(B). In contrast, other European countries had relatively low rates of erm (B) . Interestingly, the prevalence of erm(B) in Italy and Germany found in this study is much lower than in previous reports from these countries (see Table 2 ). The reasons for these shifts are unclear but chronological and geographical variations may be responsible. Isolates in the Italian study were collected between 1993 and 1997, and isolates from the German study were collected from 19 medical centres throughout Germany. In PROTEKT, only one European isolate (from Hungary) was found to have dual mechanisms of macrolide resistance [erm(B)+mef(A)].
The North American data for PROTEKT indicate that the percentage of macrolide-resistant pneumococci expressing mef(A) is 52.6% and 63.8% for Canada and the USA, respectively, in agreement with previous studies. Mexico had a similar distribution [57.1% mef(A)]. In the USA, the presence of a dual mechanism [erm(B)+mef(A)] at a rate of 12.4% is higher than the previous 1996-1997 report of 3.3% and may indicate that this genotype is increasing in prevalence. 17 It will be interesting to monitor this trend in future years of the PROTEKT study. In the Far East, rates of mef(A) and erm(B) 10 and the low rate of isolation in this global study suggests that isolates with this gene are currently a minor representation of circulating pathogens. In total, 16 S. pneumoniae isolates were negative for the mechanisms tested. These isolates are under investigation for other mechanisms of resistance. So far, in four of these strains we have found the mechanism of resistance to be ribosomal mutations. 30 These mechanisms would not have been detected without genotypic data as the phenotype predicted was either MLS B or M. As shown in Table 3 , prediction of genotype from MIC phenotype would have resulted in a 10.2% error rate. These isolates with unknown resistance mechanisms had a wide geographical distribution, having been found in Canada, the USA, Germany, Japan, Australia, Turkey and Poland. This geographical spread correlates with previous studies (Table 2) .
The comparative in vitro activity of macrolides and ketolides against the various macrolide resistance genotypes is summarized in Figure 1 and Table 4 . Telithromycin retained excellent anti-pneumococcal activity irrespective of the resistance mechanism, having an MIC 90 of 0.25, 0.5 and 0. 5 
mg/L against mef(A), erm(B) and mef(A)+erm(B)
macrolide-resistant S. pneumoniae, respectively.
S. pyogenes
With regard to S. pyogenes, all macrolide-susceptible isolates tested were negative for the mechanisms under investigation. The distribution of macrolide resistance mechanisms in the 143 macrolide-resistant S. pyogenes isolates tested is shown in Table 5 . A summary of previous studies in which S. pyogenes macrolide resistance mechanisms were investigated genotypically is shown in Table 6 . The data from PROTEKT show that the macrolide resistance mechanism distribution pattern for S. pyogenes also varied widely between countries and geographical regions. As the prevalence of macrolideresistant S. pyogenes is low, these data are difficult to analyse accurately. It is interesting that in several countries the ratio of mef-to erm-mediated resistance appears to be the reverse of Table 6 ). The comparative in vitro activity of macrolides and ketolides against the various macrolide resistance genotypes of S. pyogenes is summarized in Table 7 . Telithromycin retained excellent activity against macrolide-resistant S. pyogenes mediated by either mef(A) or erm(TR). However, its activity against erm(B) isolates was generally low.
The global distribution of macrolide resistance mechanisms may be of use in helping to understand the evolution of macrolide resistance in S. pneumoniae and S. pyogenes. There is some evidence that resistance development in a given population might be related to the level of macrolide consumption. In Finland, a decrease in macrolide consumption from 1992 to 1996 was associated with a decrease in macrolide-resistant S. pyogenes. 37 Furthermore, an association between prescribing and macrolide resistance for the longer-acting macrolides, such as clarithromycin and azithromycin, has been reported. 38 The data from these studies, although interesting and provocative, do not clearly establish causality. A properly constructed longitudinal microbiological and epidemiological study may reveal the true evolutionary process. In such a study, assessment of the development, distribution and changes in distribution of macrolide resistance mechanisms would be crucial in determining true cause and effect. isolates. MICs tested and interpreted using NCCLS methodology as described previously. 18 There are other sound reasons for determining the genotype as well as the phenotype in isolates obtained from surveillance studies. Clinically, different mechanisms result in different resistance patterns; therefore, accurate genotypic data may be a useful adjunct in determining empirical therapy and susceptibility testing guidelines for different geographical regions. As this study shows, predicting the genotype from MIC phenotypic data is not always reliable as a 10.2% error rate was observed (see Table 3 ). Also, screening for known macrolide resistance allows detection of mechanisms not previously described. Finally, the genotypically characterized strains obtained from this study will be invaluable in assessing the suitability and efficacy of new antibacterials in pre-and post-clinical phases.
